Renal Business Today

Ferrlecit

Sanofi-Aventis Releases New Ferrlecit Formulation

BRIDGEWATER, N.J.—In response to customer feedback, sanofi-aventis has started to sell its iron drug Ferrlecit in a new vial formulation, which is replacing the older ampule version in order to avoid and potential safety issues. ...More
April 22, 2011 By Keith Chartier
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
FDA Approves Generic Ferrlecit

MORRISTOWN, N.J.—The U.S. Food and Drug Administration (FDA) has approved GeneraMedix Inc.’s generic version of sanofi aventis’ iron drug Ferrlecit. ...More
March 31, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Use of AMAG’s Feraheme on the Rise

EXTON, Pa.— Six months after launching, the use of AMAG Pharmaceuticals' Feraheme is on the rise with 23 percent of nephrologists reporting use of the IV iron drug, according to new survey results from BioTrends Research Group. ...More
February 16, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management
Many New ESRD Patients Haven’t Seen Nephrologist

WASHINGTON—In 2007, many patients starting end-stage renal disease therapy received no nephrologist care, dietary counseling or therapy with erythropoietin-stimulating agents prior to treatment, suggesting that the transition to ESRD is poor in the United States, according ...More
September 23, 2009
Posted in News, Business, Clinical & Pharma, Government & Regulation
Watson, GeneraMedix to Market Generic Ferrlecit

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. announced July 29 a license agreement with GeneraMedix Inc., for the exclusive U.S. marketing rights to a generic version of Ferrlecit, a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients ...More
July 29, 2009
Posted in News, Business, Clinical & Pharma
Watson to Keep Selling Ferrlecit Until End of Year

CORONA, Calif.—Watson Pharmaceuticals said May 18 it will continue to sell the iron deficiency treatment Ferrlecit in the United States until the end of the year after a Swiss arbiter ruled in favor of the company. ...More
May 18, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More
April 28, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
Number of U.S. ESRD patients exceeds 500,000

In 2006, more than 500,000 patients received some form of end-stage renal disease therapy in the United States, and Medicare spent nearly $23 billion to care for them, according to the U.S. Renal Data System’s 2008 Annual Data Report. ...More
September 19, 2008
Posted in News, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Ferrlecit

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail